Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29010932 | 0.78 | MGLL (0.39) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL29010797 | 0.74 | MGLL (0.36) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL29010976 | 0.74 | MGLL (0.36) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL29010970 | 0.73 | HCAR1 (0.36) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL29010796 | 0.73 | HCAR1 (0.36) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL718672 | 0.73 | HCAR1 (0.36) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL23346631 | 0.72 | MGLL (0.37) | MGLLGSK3AGSK3BGMNNALDH1A1 | |
| SCHEMBL19868966 | 0.71 | GSK3A (0.30) | MGLLGSK3AGSK3B | |
| SCHEMBL29307860 | 0.70 | HSD17B10 (0.35) | MGLLGMNNALDH1A1LMNAMAPT | |
| SCHEMBL9156754 | 0.70 | GSK3A (0.32) | MGLLGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210138077-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138077-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | MGLL 1865/4885GSK3A 4709/4885GSK3B 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.